泰国的 III 期 HIV 疫苗试验：迈向 HIV 保护疫苗的一步。
Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
机构信息
Animal Models and Retroviral Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Expert Rev Vaccines. 2010 Sep;9(9):997-1005. doi: 10.1586/erv.10.104.
Abstract
The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.
摘要
泰国开展的大型人类功效试验 RV144 于 2009 年夏得出结论。这是首个表明在预防 HIV 感染方面具有一定但显著效果的 III 期试验。该试验标志着预防 HIV 的疫苗可能成为现实。在泰国进行的疫苗试验方案包括使用携带三种合成 HIV 基因的金丝雀痘载体进行初级免疫，随后用两种来自 HIV clade B 和 E 的重组包膜蛋白进行加强免疫。为了解该疫苗组合诱导的新反应在预防 HIV 感染方面的作用，许多研究人员齐聚一堂，共同目标是研发出安全有效的 HIV 疫苗。
相似文献
1
Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.泰国的 III 期 HIV 疫苗试验：迈向 HIV 保护疫苗的一步。
Expert Rev Vaccines. 2010 Sep;9(9):997-1005. doi: 10.1586/erv.10.104.
2
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.在未感染 HIV 的泰国志愿者中，用 AIDSVAX B/E 和 ALVAC-HIV 对 RV144 方案进行后期增强：一项双盲、随机对照试验。
Lancet HIV. 2020 Apr;7(4):e238-e248. doi: 10.1016/S2352-3018(19)30406-0. Epub 2020 Feb 6.
3
HIV-1 prophylactic vaccine trials in Thailand.泰国的HIV-1预防性疫苗试验。
Curr HIV Res. 2005 Jan;3(1):17-30. doi: 10.2174/1570162052772933.
4
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.C 亚型 ALVAC-HIV 和双价 C 亚型 gp120/MF59 HIV-1 疫苗在南非低危、未感染 HIV 的成年人中的 1/2 期临床试验
Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.
5
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.两种表达HIV-1基因或狂犬病病毒G蛋白基因的金丝雀痘病毒疫苗的全身和黏膜递送比较。
J Infect Dis. 2004 Apr 1;189(7):1221-31. doi: 10.1086/382088. Epub 2004 Mar 15.
6
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.RV144 和 Vax003 HIV-1 疫苗功效试验中的中和抗体反应的幅度和广度。
J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.
7
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.一种HIV-1 A/E亚型DNA初免、重组鸡痘病毒加强的疫苗是安全的，但在泰国低HIV感染风险志愿者的随机I/IIa期试验中无免疫原性。
Hum Vaccin. 2010 Oct;6(10):835-40. doi: 10.4161/hv.6.10.12635. Epub 2010 Oct 1.
8
Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.用表达 HIV-1 病毒样颗粒的 DNA 和重组痘病毒载体对中国食蟹猴进行异源初免-加强-加强免疫接种。
Virol J. 2011 Sep 7;8:429. doi: 10.1186/1743-422X-8-429.
9
Human immunodeficiency virus vaccine trials.人类免疫缺陷病毒疫苗试验。
Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a007351. doi: 10.1101/cshperspect.a007351.
10
Nonreplicating vectors in HIV vaccines.HIV 疫苗中的非复制型载体。
Curr Opin HIV AIDS. 2013 Sep;8(5):412-20. doi: 10.1097/COH.0b013e328363d3b7.
引用本文的文献
1
Enhanced HIV immune responses elicited by an apoptotic single-cycle SHIV lentivector DNA vaccine.一种凋亡性单周期猿猴免疫缺陷病毒-人免疫缺陷病毒嵌合慢病毒载体DNA疫苗引发的增强型HIV免疫反应
Front Cell Infect Microbiol. 2025 Apr 10;15:1481427. doi: 10.3389/fcimb.2025.1481427. eCollection 2025.
2
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.探索临床前和临床环境中的 HIV 疫苗进展：从历史到未来展望。
Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368.
3
Personal experiences following acquiring HIV infection while volunteering in Phase I/II HIV vaccine trials: A qualitative study from Tanzania.感染 HIV 后参与 I/II 期 HIV 疫苗试验的个人经历：来自坦桑尼亚的定性研究。
PLoS One. 2022 Oct 26;17(10):e0276404. doi: 10.1371/journal.pone.0276404. eCollection 2022.
4
SARS-CoV-2 Vaccine Development: An Overview and Perspectives.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗研发：概述与展望
ACS Pharmacol Transl Sci. 2020 Sep 18;3(5):844-858. doi: 10.1021/acsptsci.0c00109. eCollection 2020 Oct 9.
5
CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine.CCR10 表达是黏膜趋化因子 CCL28 在 HIV-1 Env DNA 疫苗背景下给予时的佐剂活性所必需的。
Vaccine. 2020 Mar 4;38(11):2626-2635. doi: 10.1016/j.vaccine.2020.01.023. Epub 2020 Feb 10.
6
Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial.使用移动技术（pMOTAR）评估反应原性：一项试点随机对照试验的方案
JMIR Res Protoc. 2018 Oct 3;7(10):e175. doi: 10.2196/resprot.9396.
7
Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques.黏膜抗体对 SIV 蛋白酶切割位点或全长 gag 和 env 蛋白疫苗的反应在毛里求斯食蟹猴中。
PLoS One. 2018 Aug 28;13(8):e0202997. doi: 10.1371/journal.pone.0202997. eCollection 2018.
8
Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines.灭活全艾滋病毒疫苗；采用一种成熟的抗病毒疫苗策略。
AIDS Res Ther. 2017 Sep 12;14(1):47. doi: 10.1186/s12981-017-0176-5.
9
Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.DNA/MVA HIV 疫苗在恒河猴模型中的免疫原性和功效。
Expert Rev Vaccines. 2017 Oct;16(10):973-985. doi: 10.1080/14760584.2017.1371594. Epub 2017 Sep 4.
10
Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.膜锚定趋化因子CCL20增强HIV包膜蛋白特异性黏膜免疫反应。
Virol J. 2017 Aug 23;14(1):163. doi: 10.1186/s12985-017-0831-4.
本文引用的文献
1
Raft of results energizes researchers.大量的研究结果激励着研究人员。
IAVI Rep. 2009 Sep-Oct;13(5):4-5, 7-13, 17.
2
Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America.北美三期艾滋病疫苗试验中 HIV-1 的系统发育动力学
Mol Biol Evol. 2010 Feb;27(2):417-25. doi: 10.1093/molbev/msp254. Epub 2009 Oct 28.
3
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
4
AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.AIDSVAX免疫接种可在随后感染HIV的高危、HIV阴性志愿者中诱导HIV特异性CD8+T细胞反应。
Vaccine. 2009 Feb 11;27(7):1136-40. doi: 10.1016/j.vaccine.2008.11.071. Epub 2008 Dec 9.
5
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.一种细胞介导免疫HIV-1疫苗的疗效评估（STEP研究）：一项双盲、随机、安慰剂对照的概念验证试验。
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.
6
The use of nonhuman primate models in HIV vaccine development.非人灵长类动物模型在HIV疫苗研发中的应用。
PLoS Med. 2008 Aug 12;5(8):e173. doi: 10.1371/journal.pmed.0050173.
7
HIV vaccine research in Thailand: lessons learned.泰国的艾滋病疫苗研究：经验教训
Expert Rev Vaccines. 2008 Apr;7(3):311-7. doi: 10.1586/14760584.7.3.311.
8
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.CRF01_AE（E亚型）候选疫苗安全性和免疫原性的1/2期比较疫苗试验：用ALVAC-HIV（vCP1521）初免，并用寡聚gp160（92TH023/LAI-DID）或二价gp120（CM235/SF2）加强免疫。
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55. doi: 10.1097/QAI.0b013e3181354bd7.
9
The spread of HIV-1 subtypes B and CRF01_AE among injecting drug users in Bangkok, Thailand.HIV-1 B亚型和CRF01_AE在泰国曼谷注射吸毒者中的传播情况。
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):468-75. doi: 10.1097/QAI.0b013e318093dea5.
10
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.泰国曼谷注射吸毒者中一种二价重组糖蛋白120 HIV-1疫苗的随机、双盲、安慰剂对照疗效试验。
J Infect Dis. 2006 Dec 15;194(12):1661-71. doi: 10.1086/508748. Epub 2006 Nov 3.
Zotero 插件